Healthcare Industry News: Venous Leg Ulcer
News Release - March 12, 2008
Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing DeviceInnovative Device Utilizes Revolutionary Electrotherapy to Improve Healing of Chronic Wounds
ALBUQUERQUE, New Mexico, March 12 (HSMN NewsFeed) -- Kingfisher Americas, a healthcare company focused on improving patient quality of life, today announced that its parent company, Belgium-based Kingfisher Healthcare, has received CE mark for its KFH Novo medical device, a breakthrough medical technology that enhances the healing of chronic wounds. KFH Novo is the latest addition to Kingfisher's line of safe, non-invasive energy therapies designed to treat patients suffering from a range of chronic conditions.
KFH Novo utilizes Kingfisher's revolutionary Bio-Electric Stimulation Therapy (BEST) to assist in and improve upon the healing of chronic wounds including Venous Leg Ulcers, diabetic ulcers and pressure sores. This unique form of electrotherapy enhances the physiological processes of wound healing at a cellular level, increasing protein synthesis levels, stimulating angiogenesis and fibroblasts, and increasing levels of ATP production to restart and regenerate tissue healing.
"Treatments for chronic wounds remain a major clinical challenge as a significant number of patients endure painful, open abrasions for as long as a year," said Dr. Henk Snyman, founder and CEO of Kingfisher Healthcare. "We are thrilled to offer physicians and patients a safe, non-invasive and cost-effective therapy designed to successfully treat several types of chronic wounds."
Designed for home use, KFH Novo is portable, convenient and easy-to-use. Its sleek and modern design elements, including patented touch-screen panel, allows patients to monitor and control their treatments. KFH Novo is expected to enter the U.S. market in 2009.
"We are pleased to announce the addition of KFH Novo to our line of innovative, alternative therapies," said Herb Whitaker, CEO of Kingfisher Americas. "We look forward to working with the European medical community to introduce this unique therapy intended to significantly improve upon each patient's quality of life."
For more information on KFH Novo please visit http://www.kfhealth.com.
About Kingfisher Americas
Kingfisher Americas, a subsidiary of the Belgium-based Kingfisher Healthcare, is the first company to use safe, non-invasive energy to treat patients suffering from chronic conditions. It utilizes a technology platform called BEST (Bio-Electric Stimulation Therapy) from which unique products are developed by Kingfisher Healthcare. Headquartered in Albuquerque, New Mexico, Kingfisher Americas focuses on establishing relationships with patients, patient support groups, and medical experts to improve the quality of life of fibromyalgia, post polio, and chronic fatigue syndrome patients. For more information, please visit http://www.kfamericas.com.
Source: Kingfisher Americas
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.